NCT05858879

Brief Summary

Estimate the impact of notifying both patients and their clinicians of the presence of incidental coronary artery calcium (CAC) on initiation of lipid-lowering therapy in patients with ASCVD who are not receiving lipid-lowering therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
233

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 15, 2023

Completed
1.4 years until next milestone

Study Start

First participant enrolled

October 22, 2024

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 24, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 24, 2026

Completed
Last Updated

April 22, 2026

Status Verified

April 1, 2026

Enrollment Period

1.4 years

First QC Date

May 5, 2023

Last Update Submit

April 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Initiation of lipid-lowering therapy

    Number of patients who had initiation of lipid-lowering therapy

    Month 6

Study Arms (3)

Notification with a CAC image

EXPERIMENTAL

Notification of presence of CAC with a CT scan image and the ACC/AHA guideline recommendation for initiation of lipid-lowering therapy.

Other: Notification of patients and clinicians

Notification without a CAC image

EXPERIMENTAL

Notification of presence of CAC without a CT scan image and the ACC/AHA guideline recommendation for initiation of lipid-lowering therapy.

Other: Notification of patients and clinicians

Usual care

NO INTERVENTION

The usual care arm will not receive any additional notification beyond the standard of care. If the intervention is successful, we will notify patients in the usual care arm of the presence of CAC and the ACC/AHA guideline recommendation for initiation of lipid-lowering therapy.

Interventions

Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan (with or without an image) and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification. Two months after the initial notification, patients and their clinicians who are randomized to notification arms will receive a second message similar to the initial notification.

Notification with a CAC imageNotification without a CAC image

Eligibility Criteria

Age18 Years - 84 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Presence of CAC on non-gated chest CT scans performed from 2021 to 2025
  • Age \<85 years
  • Diagnosis of ASCVD(coronary artery disease, peripheral artery disease, or cerebrovascular disease)
  • Visit to Stanford affiliated clinician since 2022 at one of the following Stanford clinics including University affiliated clinics:
  • Internal Medicine
  • Family Medicine
  • Cardiology
  • Neurology
  • Vascular surgery
  • Primary language is English or Spanish

You may not qualify if:

  • No diagnosis of ASCVD
  • Patients receiving lipid-lowering therapy
  • Dementia
  • Metastatic cancer or active cancer undergoing chemotherapy
  • Hospice

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University

Stanford, California, 94304, United States

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Masking Details
In the usual care arm, patients or clinicians will not be notified.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Eligible patients will be randomized to: 1) notification of presence of CAC with a CT scan image; 2) notification of presence of CAC without a CT scan image; 3) or usual care.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Medicine (Cardiovascular Medicine)

Study Record Dates

First Submitted

May 5, 2023

First Posted

May 15, 2023

Study Start

October 22, 2024

Primary Completion

March 24, 2026

Study Completion

March 24, 2026

Last Updated

April 22, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations